drugset / Trial / NCT06696443

Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)

NCT06696443

Phase 3 Active not recruiting 455 enrolled Vertex Pharmaceuticals Incorporated
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of SUZ and long-term effectiveness of SUZ in treating pain associated with DPN.

Timeline

Start
2024-12-18
Primary completion
2027-01-25
Completion
2027-01-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Suzetrigine Small molecule Oral